AAPL346.95+3.04 (+0.88%) ▲|ABBV286.48-0.26 (-0.09%) ▼|ABT103.40-1.48 (-1.41%) ▼|ACN236.25-10.98 (-4.44%) ▼|ADBE251.12-7.50 (-2.90%) ▼|AMAT398.08+10.49 (+2.71%) ▲|AMD558.56+27.28 (+5.13%) ▲|AMGN447.01+2.38 (+0.53%) ▲|AMT185.93-2.35 (-1.25%) ▼|AMZN253.31+4.22 (+1.69%) ▲|AVGO341.61+12.44 (+3.78%) ▲|AXP314.18-0.88 (-0.28%) ▼|BA169.85-18.46 (-9.80%) ▼|BAC50.60+0.08 (+0.16%) ▲|BKNG151.78-1.36 (-0.89%) ▼|BLK1,134.93+7.27 (+0.64%) ▲|BMY61.34-0.27 (-0.44%) ▼|BNY147.83+0.65 (+0.44%) ▲|BRK-B544.77-3.79 (-0.69%) ▼|C122.63+1.59 (+1.31%) ▲|CAT712.52+20.39 (+2.95%) ▲|CL92.17-0.94 (-1.00%) ▼|CMCSA21.88-0.18 (-0.79%) ▼|COF204.42+2.07 (+1.02%) ▲|COP148.36-3.01 (-1.99%) ▼|COST991.31-13.86 (-1.38%) ▼|CRM243.11-4.51 (-1.82%) ▼|CSCO112.51+2.27 (+2.05%) ▲|CVS91.79-0.74 (-0.80%) ▼|CVX228.00-4.01 (-1.73%) ▼|DE642.51+1.26 (+0.20%) ▲|DHR232.24-0.73 (-0.31%) ▼|DIS109.57-0.83 (-0.75%) ▼|DUK124.02-0.42 (-0.33%) ▼|EMR164.59+2.89 (+1.79%) ▲|FDX304.59+4.01 (+1.33%) ▲|GD356.19-0.86 (-0.24%) ▼|GE295.92+7.49 (+2.60%) ▲|GEV878.92+24.30 (+2.84%) ▲|GILD157.49-1.21 (-0.76%) ▼|GM81.00+4.69 (+6.15%) ▲|GOOG318.16+3.97 (+1.26%) ▲|GOOGL321.77+4.97 (+1.57%) ▲|GS913.08+19.80 (+2.22%) ▲|HD318.22-1.16 (-0.36%) ▼|HON217.13-2.15 (-0.98%) ▼|IBM249.61-3.83 (-1.51%) ▼|INTC93.99+3.52 (+3.89%) ▲|INTU327.03-12.86 (-3.78%) ▼|ISRG444.77-6.86 (-1.52%) ▼|JNJ267.72+1.42 (+0.53%) ▲|JPM336.11+2.07 (+0.62%) ▲|KO92.13-0.57 (-0.61%) ▼|LIN506.81-0.75 (-0.15%) ▼|LLY1,284.53+5.39 (+0.42%) ▲|LMT628.47-6.73 (-1.06%) ▼|LOW197.14-1.09 (-0.55%) ▼|LRCX241.03+3.53 (+1.49%) ▲|MA610.28-3.22 (-0.52%) ▼|MCD248.78-2.06 (-0.82%) ▼|MDLZ62.30-0.67 (-1.06%) ▼|MDT93.80-0.99 (-1.04%) ▼|META624.85-5.71 (-0.91%) ▼|MMM171.51-1.28 (-0.74%) ▼|MO73.36-0.26 (-0.35%) ▼|MRK142.17+1.56 (+1.11%) ▲|MS187.21+3.72 (+2.03%) ▲|MSFT533.73+1.13 (+0.21%) ▲|MU931.42+27.72 (+3.07%) ▲|NEE82.05+0.01 (+0.01%) ▲|NFLX62.71-1.19 (-1.86%) ▼|NKE37.46-0.46 (-1.20%) ▼|NOW155.95-2.24 (-1.41%) ▼|NVDA218.70+2.70 (+1.25%) ▲|ORCL131.76+5.70 (+4.52%) ▲|PEP133.87-1.59 (-1.17%) ▼|PFE29.72-0.08 (-0.25%) ▼|PG158.48-1.44 (-0.90%) ▼|PLTR201.02+2.18 (+1.10%) ▲|PM203.69+1.82 (+0.90%) ▲|QCOM181.20+1.60 (+0.89%) ▲|RTX195.90-1.58 (-0.80%) ▼|SBUX102.49-0.21 (-0.20%) ▼|SCHW89.61-0.12 (-0.13%) ▼|SO91.87-0.70 (-0.76%) ▼|SPG212.30-0.40 (-0.19%) ▼|T21.07+0.22 (+1.03%) ▲|TMO692.74+7.85 (+1.15%) ▲|TMUS146.97+0.04 (+0.03%) ▲|TSLA406.15+14.53 (+3.71%) ▲|TXN306.47+8.35 (+2.80%) ▲|UBER66.13+0.00 (+0.00%) ▲|UNH409.51-1.20 (-0.29%) ▼|UNP297.85+0.88 (+0.29%) ▲|UPS103.36+3.04 (+3.03%) ▲|USB59.74+0.04 (+0.06%) ▲|V400.76-3.40 (-0.84%) ▼|VZ43.84+0.74 (+1.72%) ▲|WFC82.61-0.04 (-0.05%) ▼|WMT118.94-1.36 (-1.13%) ▼|XOM181.09-3.46 (-1.87%) ▼|AAPL346.95+3.04 (+0.88%) ▲|ABBV286.48-0.26 (-0.09%) ▼|ABT103.40-1.48 (-1.41%) ▼|ACN236.25-10.98 (-4.44%) ▼|ADBE251.12-7.50 (-2.90%) ▼|AMAT398.08+10.49 (+2.71%) ▲|AMD558.56+27.28 (+5.13%) ▲|AMGN447.01+2.38 (+0.53%) ▲|AMT185.93-2.35 (-1.25%) ▼|AMZN253.31+4.22 (+1.69%) ▲|AVGO341.61+12.44 (+3.78%) ▲|AXP314.18-0.88 (-0.28%) ▼|BA169.85-18.46 (-9.80%) ▼|BAC50.60+0.08 (+0.16%) ▲|BKNG151.78-1.36 (-0.89%) ▼|BLK1,134.93+7.27 (+0.64%) ▲|BMY61.34-0.27 (-0.44%) ▼|BNY147.83+0.65 (+0.44%) ▲|BRK-B544.77-3.79 (-0.69%) ▼|C122.63+1.59 (+1.31%) ▲|CAT712.52+20.39 (+2.95%) ▲|CL92.17-0.94 (-1.00%) ▼|CMCSA21.88-0.18 (-0.79%) ▼|COF204.42+2.07 (+1.02%) ▲|COP148.36-3.01 (-1.99%) ▼|COST991.31-13.86 (-1.38%) ▼|CRM243.11-4.51 (-1.82%) ▼|CSCO112.51+2.27 (+2.05%) ▲|CVS91.79-0.74 (-0.80%) ▼|CVX228.00-4.01 (-1.73%) ▼|DE642.51+1.26 (+0.20%) ▲|DHR232.24-0.73 (-0.31%) ▼|DIS109.57-0.83 (-0.75%) ▼|DUK124.02-0.42 (-0.33%) ▼|EMR164.59+2.89 (+1.79%) ▲|FDX304.59+4.01 (+1.33%) ▲|GD356.19-0.86 (-0.24%) ▼|GE295.92+7.49 (+2.60%) ▲|GEV878.92+24.30 (+2.84%) ▲|GILD157.49-1.21 (-0.76%) ▼|GM81.00+4.69 (+6.15%) ▲|GOOG318.16+3.97 (+1.26%) ▲|GOOGL321.77+4.97 (+1.57%) ▲|GS913.08+19.80 (+2.22%) ▲|HD318.22-1.16 (-0.36%) ▼|HON217.13-2.15 (-0.98%) ▼|IBM249.61-3.83 (-1.51%) ▼|INTC93.99+3.52 (+3.89%) ▲|INTU327.03-12.86 (-3.78%) ▼|ISRG444.77-6.86 (-1.52%) ▼|JNJ267.72+1.42 (+0.53%) ▲|JPM336.11+2.07 (+0.62%) ▲|KO92.13-0.57 (-0.61%) ▼|LIN506.81-0.75 (-0.15%) ▼|LLY1,284.53+5.39 (+0.42%) ▲|LMT628.47-6.73 (-1.06%) ▼|LOW197.14-1.09 (-0.55%) ▼|LRCX241.03+3.53 (+1.49%) ▲|MA610.28-3.22 (-0.52%) ▼|MCD248.78-2.06 (-0.82%) ▼|MDLZ62.30-0.67 (-1.06%) ▼|MDT93.80-0.99 (-1.04%) ▼|META624.85-5.71 (-0.91%) ▼|MMM171.51-1.28 (-0.74%) ▼|MO73.36-0.26 (-0.35%) ▼|MRK142.17+1.56 (+1.11%) ▲|MS187.21+3.72 (+2.03%) ▲|MSFT533.73+1.13 (+0.21%) ▲|MU931.42+27.72 (+3.07%) ▲|NEE82.05+0.01 (+0.01%) ▲|NFLX62.71-1.19 (-1.86%) ▼|NKE37.46-0.46 (-1.20%) ▼|NOW155.95-2.24 (-1.41%) ▼|NVDA218.70+2.70 (+1.25%) ▲|ORCL131.76+5.70 (+4.52%) ▲|PEP133.87-1.59 (-1.17%) ▼|PFE29.72-0.08 (-0.25%) ▼|PG158.48-1.44 (-0.90%) ▼|PLTR201.02+2.18 (+1.10%) ▲|PM203.69+1.82 (+0.90%) ▲|QCOM181.20+1.60 (+0.89%) ▲|RTX195.90-1.58 (-0.80%) ▼|SBUX102.49-0.21 (-0.20%) ▼|SCHW89.61-0.12 (-0.13%) ▼|SO91.87-0.70 (-0.76%) ▼|SPG212.30-0.40 (-0.19%) ▼|T21.07+0.22 (+1.03%) ▲|TMO692.74+7.85 (+1.15%) ▲|TMUS146.97+0.04 (+0.03%) ▲|TSLA406.15+14.53 (+3.71%) ▲|TXN306.47+8.35 (+2.80%) ▲|UBER66.13+0.00 (+0.00%) ▲|UNH409.51-1.20 (-0.29%) ▼|UNP297.85+0.88 (+0.29%) ▲|UPS103.36+3.04 (+3.03%) ▲|USB59.74+0.04 (+0.06%) ▲|V400.76-3.40 (-0.84%) ▼|VZ43.84+0.74 (+1.72%) ▲|WFC82.61-0.04 (-0.05%) ▼|WMT118.94-1.36 (-1.13%) ▼|XOM181.09-3.46 (-1.87%) ▼|
14.6 C
New York
Tuesday, October 27, 2026

Tag: inhibitors

newsFORsourcecompanycontentinformation1releasesmarket

Cancer Cachexia Market Anticipates Impressive Growth Trajectory at a CAGR of 8.9% During the Forecast Period (2025-2034) | DelveInsight

The cancer cachexia market is expected to witness an expansion across the 7MM, driven by the introduction of innovative therapies, ponsegromab (PF-06946860), S-pindolol benzoate...

Ascentage Pharma Appoints Dr. Veet Misra as Chief Financial Officer and Eric Huang as Senior Vice President of Global Corporate Development and Finance

ROCKVILLE, Md. and SUZHOU, China, July 07, 2025 (GLOBE NEWSWIRE) -- Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855) (“Ascentage Pharma” or the “Company”), a global biopharmaceutical company dedicated to addressing unmet medical needs in cancers, announced the appointments of Veet Misra, Ph.D., as the Company’s Chief Financial Officer, and Mr. Eric Huang, as Senior Vice President of Global Corporate Development and Finance. Both Dr. Misra and Mr. Huang will report directly to Dajun Yang, M.D., Ph.D., the Company’s Chairman & Chief Executive Officer.

NANOBIOTIX Announces Regulatory Harmonization and New Composition of Matter Patent Filed for JNJ-1900 (NBTXR3)

PARIS and CAMBRIDGE, Mass., July 07, 2025 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘Company’’),  a late-stage clinical biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, today announced two important developments that aim to reinforce the global positioning of potential first-in-class radioenhancer JNJ-1900 (NBTXR3), which is licensed by Janssen Pharmaceutica NV, a Johnson & Johnson company.

HotSpot Therapeutics Presents Preclinical Data from Small Molecule CBM Signalosome Inhibitor Program at ESMO Gastrointestinal Cancers Congress 2025

BOSTON, July 4, 2025 /PRNewswire/ -- HotSpot Therapeutics, Inc., a biotechnology company pioneering the discovery and development of oral, small molecule allosteric therapies targeting Smart...

Everest Medicines Showcases Breakthroughs in Proprietary AI-Powered mRNA Platform at 2025 R&D Day Held in Shanghai

SHANGHAI, July 4, 2025 /PRNewswire/ -- Everest Medicines (HKEX: 1952.HK), a biopharmaceutical company focused on the discovery, clinical development, manufacturing and commercialization of innovative...

AB Science: Masitinib receives FDA and EMA authorization for confirmatory phase 3 trial in metastatic castrate-resistant prostate cancer

PRESS RELEASE

GPRC5D-directed Therapies Market is Anticipated to Gain Momentum During the Forecast Period (2025-2034) Owing to Unmet Need in Multiple Myeloma | DelveInsight

The GPRC5D-directed therapies market is witnessing robust growth, driven by the high unmet need in relapsed/refractory multiple myeloma. Innovative modalities like CAR-T cells, bispecific...

GPRC5D-directed Therapies Market is Anticipated to Gain Momentum During the Forecast Period (2025-2034) Owing to Unmet Need in Multiple Myeloma | DelveInsight

The GPRC5D-directed therapies market is witnessing robust growth, driven by the high unmet need in relapsed/refractory multiple myeloma. Innovative modalities like CAR-T cells, bispecific...

Innovative Molecules Offer Good News in the Fight Against HIV and Other Viral Infections

INRS team is exploring the potential of saponins, a group of natural molecules found in many plants LAVAL, QC, July 3, 2025 /CNW/ - Innovative, nontoxic...

OXLUMO® (lumasiran injection) Now Reimbursed in Canada For the Treatment of Primary Hyperoxaluria Type 1 (PH1) in Pediatric and Adult Patients

OXLUMO has been shown to significantly reduce urinary oxalate, which drives the progression of PH1 Disease1 MISSISSAUGA, ON, July 2, 2025 /CNW/ - Alnylam Canada ULC...

Marengo Presents Monotherapy Activity of Invikafusp Alfa, a First-in-Class Selective Dual T Cell Agonist in PD-1 Resistant GI Tumors, as a Late-Breaking Oral Presentation...

Promising monotherapy activity observed in all three major metastatic colorectal cancer subtypes harboring high tumor mutational burden (MSS RASwt, MSS RASmut and PD-1 resistant MSI-H)...

Everest Medicines Announces Updated Positive Results in Preliminary Analysis of Phase 1b/2a Clinical Trial of EVER001, a Novel BTK Inhibitor for the Treatment of...

As of March 21st, 2025, longer follow-up data was collected from the ongoing Ph1b/2a study of EVER001: in Cohort 1, 11 patients completed 52...

NADPH Oxidase (NOX)-Replacement Therapies Market to Observe Stunning Growth During the Forecast Period (2025-2034) Across 7MM | DelveInsight

The NOX-targeted therapy market is expected to expand significantly over the upcoming years as more therapies move into late-stage development and gain regulatory approval....

NADPH Oxidase (NOX)-Replacement Therapies Market to Observe Stunning Growth During the Forecast Period (2025-2034) Across 7MM | DelveInsight

The NOX-targeted therapy market is expected to expand significantly over the upcoming years as more therapies move into late-stage development and gain regulatory approval....

- A word from our sponsors -

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsInhibitors

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers